Centrum Badan Klinicznych Piotr Napora Lekarze sp.p.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The research at Centrum Badan Klinicznych Piotr Napora Lekarze sp.p. focuses on atrial fibrillation and its complications, aiming to reduce the incidence of ischemic stroke in patients who cannot use oral anticoagulants. The trials evaluate the safety and effectiveness of novel agents that may offer an alternative to standard therapy.
- Evaluating a new monoclonal antibody for stroke risk reduction
- Assessing safety profiles in high‑risk cardiac patients
- Comparing outcomes with existing anticoagulation strategies
With a total of eight ongoing studies, the site in Wroclaw contributes valuable data to cardiovascular research, involving five dedicated investigators.
Digestive System Diseases
Investigations target conditions such as ulcerative colitis, cholestasis, and hepatic complications of cirrhosis. Trials test oral therapies like NX‑13 and evaluate long‑term safety of linerixibat for cholestatic pruritus, while also exploring rifaximin to delay hepatic encephalopathy‑related hospitalizations.
- Oral NX‑13 efficacy in moderate to severe ulcerative colitis
- Long‑term safety of linerixibat for cholestatic itch
- Rifaximin formulation to prevent encephalopathy decompensation
The centre’s multidisciplinary team is advancing therapeutic options for liver and intestinal diseases, supporting patients across Poland and Europe.
Respiratory Tract Diseases
The site conducts studies on asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis. Research includes biologics such as astegolimab to lower COPD exacerbations, add‑on inhaled treatments like CHF6001 to improve asthma control, and long‑term assessment of BI 1291583 in bronchiectasis patients.
- Astegolimab efficacy in reducing COPD flare‑ups
- CHF6001 as adjunct therapy for persistent asthma
- BI 1291583 safety in chronic bronchiectasis
- Tanimilast evaluation in uncontrolled asthma on background therapy
These respiratory trials enhance understanding of disease management and aim to improve quality of life for individuals with chronic lung conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 60 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 52 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
- 1Taiho Oncology Inc.3active
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Chiesi Farmaceutici S.p.A.7trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Badan Klinicznych Piotr Napora Lekarze sp.p.
lock Showing 1 of 58 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 60 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Beclometasone Dipropionate Anhydrous | 4 | Unknown | 2022-04-22 | 2026-04-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.